Why laboratories choose pens and cartridges
A contained 3ml presentation supports clear product identification, consistent format comparison and documented repeat procurement. Compatible refill cartridges also allow an organisation to retain its reusable pen hardware while ordering the required prepared research presentation separately.
This item is prepared only after ordering to minimise elapsed time in the prepared state before dispatch. Refrigerate at 2-8 C and protect from light on receipt. Stability is compound-, preparation- and storage-dependent, so retain and follow the supplied product and batch documentation.
Tirzepatide Refill Cartridge specifications and research profile
Specifications summary
| Designation | Fatty-acid-modified dual incretin-receptor agonist |
|---|---|
| Also known as | LY3298176; Tirzepatide |
| Sequence / composition | Engineered peptide agonist of GIPR and GLP-1R |
| Strength | 120mg 3ml cartridge |
| Presentation | Refill cartridge |
| Purity | 99%+ HPLC |
| Storage | Store refrigerated at 2-8 C, protected from light. |
| COA | Batch document added when available |
Description and research context
Tirzepatide (LY3298176) is a fatty-acid-modified peptide engineered for agonist activity at the GIP and GLP-1 receptors. The dual-receptor design provides a defined comparator for studies of selective GLP-1R agonism, selective GIPR agonism and combined incretin-receptor signalling.
Discovery studies characterised receptor activation in recombinant and endogenous cell systems, including signalling and functional assays. Further preclinical work has examined the contribution of GIPR activity to the compound's molecular profile. Findings depend on receptor expression, assay design and experimental model.
Applications in research
- GIPR and GLP-1R binding, potency and cAMP-response assays
- Dual- versus single-receptor agonist comparison
- Receptor contribution and pathway-interaction studies
Precautions and interpretation
For controlled laboratory research only. Not for human or veterinary use. The cited findings come from specific biochemical, cellular, structural or preclinical models and must not be treated as usage guidance or evidence of a defined outcome outside those models.
Tirzepatide Refill Cartridge research record
Clear product, batch, storage, dispatch and document information for this refill cartridge.
Research context
A prepared 3ml refill-cartridge presentation for the same documented research context as the tirzepatide powder vial.
Product record
The listing identifies the presentation, specification, storage record, dispatch status, and COA availability for the relevant product or batch.
Use restriction
For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.